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ABSTRACT
Colorectal cancer (CRC) is the third most com-
mon cancer worldwide. Primary care profes-
sionals can play an important role in both
prevention and early detection of CRC. Most
CRCs are attributed to modifiable lifestyle fac-
tors, which can be addressed within primary
care, and promotion of population-based
screening programmes can aid early cancer
detection in asymptomatic patients. Primary
care professionals have a vital role in clinically
assessing patients presenting with symptoms
that may indicate cancer, as most patients with
CRC first present with symptoms. These
assessments are often challenging—many of the
symptoms of CRC are non-specific and com-
monly occur in patients presenting with non-
malignant disease. The range of options for
investigating symptomatic patients in primary
care is rapidly growing. Simple tests, such as
faecal immunochemical testing (FIT), are now
being used to guide decisions around referral for
more invasive tests, such as colonoscopy, while
direct access to specialist investigations is also
becoming more common. Clinical decision
support tools (CDSTs) which calculate cancer
risk based on symptomatology, patient charac-
teristics and test results can provide an addi-
tional resource to guide decisions on further
investigation. This article explores the chal-
lenges of CRC prevention and detection from
the primary care perspective, discusses current
evidence-based approaches for CRC detection
used in primary care (with examples from UK
guidelines), and highlights emerging research
which may likely alter practice in the future.
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Key Summary Points
Colorectal cancer (CRC) is the third most
common cancer worldwide; primary care
has a key role in its prevention and early
detection.
Symptom assessment in primary care is
challenging as CRC symptoms are often
common and non-specific, but there are
several options to guide decisions around
referrals and examinations.
This article provides a practical resource
for primary care professionals, describing
current evidence-based approaches and
emerging research for the early detection
of CRC, including the increasing role of
the faecal immunochemical test (FIT) for
triaging symptomatic patients in primary
care.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article, go to https://doi.org/10.6084/
m9.figshare.14270441.
INTRODUCTION
Colorectal cancer (CRC), comprising cancers of
the colon and rectum, is the third most com-
mon cancer type and the second most common
cause of cancer death worldwide, with over
800,000 deaths globally in 2018 [1–3]. Most
CRCs develop from adenomatous polyps or
adenomas; the most common subtype of CRC is
adenocarcinoma (85% of cases) [4]. CRC diag-
nosed at later stages is associated with shorter
survival time [5]. In England, while 5-year age-
standardised survival rates are 91.7%, 84.1%
and 64.9% when CRC is diagnosed in stages I, II
and III (respectively), this is reduced to 10.3%
when diagnosed with metastases at stage IV [6].
In countries where general practitioners
(GPs) play a gatekeeping role, patients usually
present first in primary care with symptoms that
may indicate cancer. However, many of the
gastrointestinal symptoms caused by CRC, such
as change in bowel habit, are common, often
non-specific, and most people presenting with
them will not have cancer [7–9]. This presents a
key diagnostic challenge for GPs—how to
promptly identify the small number of symp-
tomatic patients with cancer from the large
number without? To facilitate this, a number of
guidelines, diagnostic tools and strategies have
been developed.
This review offers a practical resource for
primary care professionals when assessing
patients with possible CRC symptoms. First, we
discuss the epidemiology of the disease and the
role of CRC screening, outlining how primary
care may contribute to this. Then, we focus on
the clinical assessment of patients in primary
care, providing specific UK examples (with rel-
evance to primary care in other countries).
Finally, we highlight promising diagnostic
developments.
This article is based on previously conducted
studies and does not involve any new studies of




Globally (although with substantial hetero-
geneity), age-standardised incidence rates for
CRC have increased in the past 30 years [10].
Increases are occurring in less developed coun-
tries in Eastern Europe, Asia and South America,
while trends towards stabilisation or decreased
rates are noted across highly developed coun-
tries such as the UK [3]. Beyond population
ageing, rises in incidence can be attributed to
changes in lifestyle including alcohol con-
sumption, obesity, smoking, limited physical
activity and poor diet (i.e. red and processed
meat consumption, insufficient fibre and cal-
cium) [3, 4, 10–12]. Figure 1 describes several
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lifestyle factors which can protect or increase
CRC risk. In the USA, CRC has the second
highest number of cancer cases and deaths
attributed to lifestyle factors [11]. In the UK,
over half of CRC cases can be attributed to
lifestyle factors [12]. For primary care, the key
implication is that behaviour change interven-
tions, such as those focusing on diet or physical
activity, may help to reduce CRC burden [13].
In contrast with incidence rates, age-stan-
dardised mortality rates (again with substantial
heterogeneity) have decreased worldwide [10];
this has been attributed to the introduction of
organised screening programmes and other
strategies to promote early cancer diagnosis
(e.g. urgent referral pathways; rapid access to
diagnostics), and improvements in treatment
[3, 4, 10].
Worldwide, CRC is more common in men
than women (a 1.47 male-to-female ratio in
incidence rates) [4]. CRC risk increases with age,
with nine in ten cases diagnosed among people
aged 50 years and older [15, 16]. Nevertheless,
recent studies in developed countries (including
the USA, Canada, Australia and the UK) show
significant increases in incidence rates among
those under 50 [17–20]. It is important to be
mindful of these changes when assessing
younger patients presenting with relevant
symptoms in primary care.
Certain populations are at a higher risk of
CRC (Fig. 1); these include those with genetic
conditions such as Lynch syndrome [4]. Per-
sonal history of colorectal adenomas and/or
family history of CRC (a two-fold increase in
risk if a first-degree relative has CRC) are also
known risk factors [4]. Other conditions that
increase CRC risk include the main inflamma-
tory bowel diseases (IBDs) ulcerative colitis and
Crohn’s disease, particularly if conditions are
untreated, severe, or are present for a longer
time period [4]. Surveillance is often recom-
mended in these cases [21–23].
SCREENING
Organised CRC screening programmes aim to
identify cancer in asymptomatic patients (when
the disease is more likely to be at early stage)
Fig. 1 Protective and risk factors for colorectal cancer. Source: Created with evidence from [4, 14]
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and has been shown to reduce CRC mortality
[24–28]. Screening also facilitates removal of
adenomas and other polyps before they become
cancerous, helping to prevent CRC [4]. Popula-
tion-based CRC screening is well established in
several countries worldwide (including the UK,
USA and Australia), with variation in the
screening tests used, time intervals and eligi-
bility criteria [29]. In England andWales, people
aged between 60 and 74 are invited by post to
participate in a biannual screening programme;
the age threshold is lower in Scotland (50–-
74 years) [30]. While population-based CRC
screening is not usually carried out in primary
care, substantial international and UK evidence
show that primary care endorsement (such as
sending personalised reminder letters or dis-
cussing pros and cons of screening with
patients) has a key role in improving CRC
screening participation [31–37].
The faecal immunochemical test (FIT) was
recently introduced in the UK, replacing the
guaiac faecal occult blood test (gFOBT) to detect
occult blood in asymptomatic individuals [38].
FIT has several advantages over gFOBT, includ-
ing an increased sensitivity and specificity,
better sensitivity to detect advanced adenomas,
and only requires a single stool sample. FIT is
specific to human haemoglobin, does not
require dietary restrictions, and the results are
unaffected by the use of non-steroidal anti-in-
flammatory drugs (NSAIDs) and anticoagulants
[39–42]. Using FIT instead of gFOBT also
increases screening participation [40, 43–46].
FIT thresholds/cut-off points for screening vary,
even across UK countries (currently 80 lg/g in
Scotland, 120 lg/g in England and 150 lg/g in
Wales) [47–49]. Those with a result at/above the
threshold are referred for a colonoscopy. In
addition to FIT, individuals aged 55 in some UK
areas are invited to participate in a ‘one-off’
screening sigmoidoscopy, estimated to have led
to a 26% reduction of CRC incidence two dec-
ades post-intervention [50].
Organised screening identifies a minority of
CRCs, with a recent study involving six highly
developed countries estimating from 6.3% to
31.4% of all diagnoses [51]. In England, the
most recent National Cancer Registration and
Analysis Service analysis of routes to diagnosis
show the proportion to be 8% (from 2006 to
2016) [52]. This highlights the need to engage
with screening to maximise informed partici-
pation, and also shows the vital role of clinically
assessing patients presenting with symptoms in
primary care for CRC—this is how most patients
with the disease present.
SYMPTOMATIC PRESENTATION
IN PRIMARY CARE
Most patients diagnosed with CRC will have
presented in primary care with one or more
abdominal complaints before diagnosis [53, 54].
Lower gastrointestinal symptoms require clini-
cal and family history, physical examination
(including abdominal and rectal examination),
and routine blood tests (to exclude anaemia and
other clinical features) [55]. Symptoms may
overlap for cancer and other non-malignant
gastrointestinal conditions such as diverticular
disease or diverticulitis, IBD, and irritable bowel
syndrome (IBS). Figure 2 describes the National
Institute for Health and Care Excellence (NICE)
guidance (adopted in England, Wales and
Northern Ireland) for diagnosing such condi-
tions when cancer is not suspected [56–58].
Safety-netting is required if no causes for the
presenting symptoms are identified and they
persist over time [59, 60].
CRC has a broad symptom signature (Fig. 3)
with varying predictive value [61]. Rectal
bleeding is a common presenting symptom
although wide variation is reported across
studies (16–60%); a large proportion of patients
with CRC will not present with this symptom
[61, 62]. Other common presenting symptoms
are abdominal pain, weight loss, tiredness and
changes in bowel habit, particularly looser or
more frequent stools [61]. Important clinical
features of CRC are iron-deficiency anaemia,
abdominal tenderness and abnormal rectal
examination [63]. If multiple symptoms/fea-
tures are present, this increases the likelihood of
a patient having CRC but positive predictive
values (PPV; the chance of a patient with a
symptom/feature combination having cancer)
rarely exceed 10% [9, 63].
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There is also emerging evidence that raised
platelet count (thrombocytosis) is a risk marker
for different types of cancer, including CRC
[55, 67]. Raised inflammatory markers (C-reac-
tive protein, erythrocyte sedimentation rate and
plasma viscosity) are associated with an
increased risk of cancer, but the sensitivity for
these markers is too low to warrant their use to
rule out CRC in primary care [68].
Fig. 2 Common non-malignant bowel conditions and associated NICE guidance. Source: created with evidence from
NICE guidance [56–58]
Fig. 3 Symptoms and clinical features that may indicate CRC. Source: created with evidence from [64–66]
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REFERRAL AND INVESTIGATIONS
The 2015 NICE guidelines for patients with a
suspicion of cancer (known as urgent or 2-week
wait referrals) uses age-based symptom cut-offs
for patients presenting with alarm or ‘‘red flag’’
symptoms and/or clinical features which have a
PPV of 3% or higher (Fig. 4) [65]. This pathway
ensures that patients with such features have
rapid diagnostic assessments, most often a
colonoscopy. Increased use of the urgent refer-
ral pathway has shown to be significantly asso-
ciated with lower CRC mortality, although no
associations have yet been found between
pathway use and reduction in late-stage cancers
[69, 70].
Non-specific symptoms or vague, ‘‘low-risk
but not no-risk symptoms’’ that do not meet the
urgent referral threshold still carry a risk of
cancer [63]; younger patients with such symp-
toms may also need to be investigated. The
2017 NICE guidelines DG30 [38] (Fig. 4) rec-
ommends these patients are offered FIT by GPs,
using one of three FIT assays: OC Sensor, HM-
JACKarc or FOB Gold [38]. Specifically, FIT
should be offered for patients without rectal
bleeding who have unexplained symptoms that
do not meet criteria for urgent referral. FIT for
symptomatic patients uses a threshold of 10 lg
Hb/g faeces—much lower than that adopted
when FIT is used for screening (recognising the
increase in risk for symptomatic patients).
Because of the different thresholds, patients
meeting criteria should still be offered a FIT
even with a recent negative screening result. If
the FIT result is positive, the patient can be
urgently referred.
A review that informed NICE DG30 reported
that at a 10 lg Hb/g level, FIT had sensitivity
between 92% and 100% and could rule out CRC
in approximately 75–80% of all symptomatic
patients. The negative predictive value (which
Fig. 4 NICE guidelines when there is a suspicion of CRC. Source: Created with evidence from [38, 65]
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takes into account disease prevalence) ranged
from 99.4% to 100% [71, 72]. When the result is
negative the clinician can be confident the
patient is very unlikely to have CRC, and pro-
vide reassurance. Unnecessary colonoscopies or
similar investigations are also avoided. Vigi-
lance is crucial in primary care, both when
results are positive and patients are not diag-
nosed with cancer, and when results are nega-
tive. While most patients with a positive FIT
result will not have cancer (a recent study
showed that 7% of those with a positive FIT had
CRC) [73], many will have another significant
bowel disease [72]. Since it is still possible
(though very unlikely) that a patient with a
negative FIT result has cancer, GPs should
emphasise the need for patients to seek help if
symptoms persist (safety-netting) [59].
Most of the studies that informed the NICE
DG30 were carried out in secondary care pop-
ulations, and only a few countries (including
England, Australia and Spain) officially recom-
mend using FIT in primary care to triage
patients [74]. Since the guidelines were pub-
lished, further studies have provided more evi-
dence on FIT’s utility in primary care, not only
to rule out (most evidence) but also to rule in
(least evidence) CRC [59, 73, 75–81]. While a
recent survey of 1024 GPs in England found
that less than half recognised DG30 [82], it is
likely that awareness has increased recently
owing to FIT availability, and the increasing use
of FIT as a result of limited colonoscopy capac-
ity exacerbated by the COVID-19 pandemic,
including to triage patients referred on the
urgent pathway [83, 84]. While some guidance
has been published on such use [85], evidence
on its impact is still limited and it is unclear
whether FIT will continue to be used as such
(and to what extent) after the COVID-19
pandemic.
DIAGNOSIS
Colonoscopy remains the gold standard inves-
tigation for diagnosing colorectal cancer, with
histological proof of diagnosis through a biopsy
[64]. It is highly sensitive (89–98% for adeno-
mas of at least 10 mm in size, and 75–93% for
adenomas of at least 6 mm in size), [42] and has
a relatively low risk of complications, with low
perforation (0.08–0.2 per 1000 procedures) and
bleeding rates (0.8–2.4 per 1000 procedures) [4].
Alternative investigations are available to deal
with limited colonoscopy availability and to
meet patient needs when colonoscopy is con-
traindicated (e.g. frail elderly). These include
flexible sigmoidoscopy and the less invasive CT
colonography (also called virtual colonoscopy)
[64]. While CT colonography is a safe alterna-
tive to colonoscopy, it has been found to be less
sensitive for smaller polyps [4, 86] (this could be
due to perceptual errors that may be improved
with training) [87], has a lower detection rate
for high-risk serrated lesions [88] and is associ-
ated with higher referral rates for additional
examinations [89]. Colon capsule endoscopy
(patient swallows a camera pill that takes pic-
tures of the bowel as it passes through—these
pictures are beamed to a recording device that
the patient wears at their waist) is a new alter-
native. Previously only used in the specialist
setting because of its high cost [9, 90], recent
limited availability of colonoscopy and patient
reluctance to undergo testing in hospital set-
tings because of the COVID-19 pandemic has
led to its evaluation as a triage test for moderate
to high-risk symptomatic patients [91]. Colon




This section describes recent developments with
applicability to primary care settings: electronic
tools to aid risk assessment and triage, GP direct
access to tests, development of rapid diagnostic
centres, and use of novel biomarkers. Artificial
intelligence may also aid CRC diagnosis in the
future, but evidence is still limited [9, 93, 94].
Electronic Tools to Aid Risk Assessment
and Triage
Clinical decision support tools (CDSTs) have
been developed to allow GPs to make the most
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of data available in patient medical records
(such as symptoms, patient characteristics such
as age and sex and test results) in order to cal-
culate patients’ risk of cancer [95–97] (Box 1).
Box 1. Risk Prediction Tools and Models
In the UK, the best known risk prediction tools
are the electronicRiskAssessmentTools (eRATs)
[63, 98], QCancer [99–101] and MacMillan
Clinical Decision Support tools which combine
eRATs andQCancer [102]. eRATswere derived
from case–control studies in primary care and
estimate cancer risk for each patient, describing
the PPV for single or repeated symptoms [98]. A
trial evaluating their clinical and cost effec-
tiveness is under way [103]. QCancer was
derived from a primary care database (QRe-
search); it estimates cancer risk for symptomatic
or asymptomatic individuals, considering not
only symptoms but other risk factors such as
age, sex, smoking status and family history [99].
Recent evidence indicates that although widely
available, such risk prediction tools are still
underused in primary care [104]. While they
may benefit clinical decision-making, several
challenges with implementation have been
highlighted [105, 106].
More recent risk predictionmodels combine
patient data and results from biomarker tests.
Examples include the CEDAR trial in the
Netherlandswhich combined routine datawith
results from FIT and faecal calprotectin to rule
out significant colorectal diseases [107], and the
COLONPREDICT studies in Spain thatvalidated
a CRC prediction model based on clinical
information and test results (FIT and other
biomarkers) and developed a score (FAST) to
predict CRC using FIT results, age and sex
[108, 109]. The FAST score has recently been
evaluated in Scotland; results showed it did not
enhance the utility of FIT used alone [110].
Direct Access to Tests and Development
of Rapid Diagnostic Centres
Recognising challenges in diagnosing cancers
with varied symptomatology, different diag-
nostic pathways have been pioneered in
Denmark, with urgent referrals for both alarm
symptoms and serious, non-specific symptoms
(GP triage is required for the latter—with direct
access to investigations) and the use of diag-
nostic centres (also with direct access) for vague
symptoms [111]. Similar approaches have been
adopted in Norway and Sweden [112, 113], and
tested in England as part of the ‘‘Accelerate,
Coordinate, Evaluate’’ (ACE) programme
[114–116]. Informed by ACE results, the 2019
National Health Service (NHS) long-term plan
stipulates the creation of Rapid Diagnostic
Centres (RDCs). These will initially focus on
cancers associated with non-specific symptoms,
followed by wider implementation for all
patients with suspected cancer, including self-
referral for red flag symptoms [117, 118].
A key aspect of these new pathways is direct
access to specialist tests and imaging, recognis-
ing evidence of health system factors (particu-
larly GP gatekeeping) on cancer outcomes
[119–121]. Earlier strategies in England already
included specific investment on GP direct access
to CT scans and flexible sigmoidoscopy
[122, 123] and laboratory tests [124]. Nonethe-
less, substantial regional variation in access is
acknowledged [125]. Wide variations are there-
fore likely in terms of access and availability of
RDCs.
Use of Novel Biomarkers
There has been substantial research in the
development of biomarkers other than FIT for
the detection of CRC; these include proteins,
volatile organic compounds, stool DNA and
liquid biopsy (comprising circulating tumour
cells and cell-free DNA) [126, 127]. The methy-
lated SEPT9 gene is a promising biomarker
[128–131]. However, evidence is scarce for the
primary care setting, and this makes clinical
applicability uncertain because of spectrum
effect/bias (variation in performance due to
testing in different populations) [130, 132].
CONCLUSION
Primary care professionals have a vital role in
the timely diagnosis of CRC. They can also help
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with prevention through behavioural interven-
tions aiming at lifestyle changes and facilitating
informed CRC screening participation. Impor-
tantly, most patients will present in primary
care with lower gastrointestinal symptoms
before being diagnosed. Diverse symptomatol-
ogy requires the use of different pathways to
diagnosis; guidance is available to facilitate this.
Diagnostic tests to triage patients are available,
along with promising emerging tools. Further
innovations are required to deal with an
increasing need for diagnostic investigations.
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